

Patient Alert Card



Important Safety Information

Please keep this card with you at all times

- This patient alert card contains important safety information that you need to be aware of before, during, and after treatment with WELIREG (belzutifan)
- Show this card to any health care professional involved in your care
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Side effects should also be reported to MSD on Tel: 0208 154 8000. By reporting side effects, you can help provide more information on the safety of this medicine

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. You are encouraged to report any suspected side effects.

Important Safety Information for Patients

Welireg can cause low oxygen levels in your body that can be severe and may require you to stop treatment, receive oxygen therapy, or be hospitalised. This is called 'hypoxia'. Your healthcare provider will monitor your oxygen levels before you start and during treatment with Welireg.

Contact your doctor immediately if you experience any of the following:

- Difficulty breathing or shortness of breath
- Increased heart rate
- Rapid breathing
- Feeling anxious or restless
- Bluish discoloration of the skin and around your mouth
- You are unable to complete sentences when at rest due to breathlessness
- Unusual tiredness
- Confusion

If these signs or symptoms become severe or are rapidly worsening then go to your nearest Accident and Emergency department or call 999 immediately to seek medical advice.

Important Contact Information

Name of specialist

Specialist phone number

Specialist after-hours phone number

My name

My phone

Emergency contact (name)

Emergency contact (phone number)

Important Information for Healthcare Providers

Please note that this patient is receiving treatment with Welireg (belzutifan) for the treatment of adult patients with VHL disease who require therapy for VHL-associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumours (pNET), and for whom localised procedures are unsuitable or undesirable.

Welireg may increase the risk of hypoxia. Please refer to the product information regarding the management of hypoxia.

For more information, consult the Welireg Patient Information Leaflet at <https://www.medicines.org.uk/emc/> or call MSD Medical Information on Tel: 0208 154 8000

